AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1513607 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 30 mg/kg/day in two divided doses for 10 days
Number of subjects: 290
Study 1513607 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 40 mg/kg/day in three divided doses for 10 days
Number of subjects: 290
Study 1513607 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 30 mg/kg/day in two divided doses for 7 days
Number of subjects: 290
Study 1513607 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 40 mg/kg/day in three divided doses for 7 days
Number of subjects: 290
Study 3884968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with supplemental essential amino acids (80% nitrogen as essential amino acids)
Number of subjects: 6
Study 3884968 — intervention group
Group type: COMPARATOR
Intervention: Diet with nonessential amino acids (80% nitrogen as nonessential amino acids)
Number of subjects: 6
Study 31268891 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid insomnia
Number of subjects: 17920
Study 29199551 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus brasiliensis supplementation
Number of subjects: 5
Study 29199551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 25394638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 17
Study 25394638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 24887336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (0.5 µg/kg, 1 mL)
Number of subjects: 60
Study 24887336 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (0.5 µg/kg, 20 mL)
Number of subjects: 60
Study 23164044 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) patient education program in primary health care, conducted by trained district nurses, 13 sessions of 2 hours each over one year.
Number of subjects: 165
Study 23164044 — intervention group
Group type: COMPARATOR
Intervention: Standardized home-sent patient information, 11 occasions during the year.
Number of subjects: 165
Study 19910831 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Periodization (LP)
Number of subjects: 40
Study 19910831 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 40
Study 17302653 — intervention group
Group type: EXPERIMENTAL
Intervention: glargine+OAD
Number of subjects: 130
Study 17302653 — intervention group
Group type: COMPARATOR
Intervention: 70/30
Number of subjects: 130
Study 15151839 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐CRP and TC/HDL‐C ratio
Number of subjects: 240
Study 15151839 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐CRP
Number of subjects: 240
Study 15151839 — intervention group
Group type: EXPERIMENTAL
Intervention: TC/HDL‐C
Number of subjects: 240
Study 15151839 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐CRP combined with TC/HDL‐C
Number of subjects: 240
Study 11831545 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 mg rofecoxib
Number of subjects: 18
Study 11831545 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 18
Study 10192855 — intervention group
Group type: EXPERIMENTAL
Intervention: DDIR pacing
Number of subjects: 15
Study 10192855 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing with mode switch
Number of subjects: 15
Study 10192855 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study 7749286 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled Roux-en-Y anastomosis
Number of subjects: 22
Study 7749286 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn Roux-en-Y anastomosis
Number of subjects: 22
Study 2261900 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary counselling aimed at reducing dietary fat intake to 20‐25% of energy while increasing intake of carbohydrates
Number of subjects: 240
Study 2261900 — intervention group
Group type: COMPARATOR
Intervention: No dietary advice
Number of subjects: 240
Study 7446596 — intervention group
Group type: EXPERIMENTAL
Intervention: Respond as quickly and accurately as possible
Number of subjects: 16
Study 7446596 — intervention group
Group type: COMPARATOR
Intervention: Respond accurately with praise for slower RT
Number of subjects: 16
Study 7446596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-exposure durations varied randomly
Number of subjects: 16
Study 7446596 — intervention group
Group type: COMPARATOR
Intervention: Stimulus-exposure durations arranged in regular blocks from long to short
Number of subjects: 16
Study 7446596 — intervention group
Group type: EXPERIMENTAL
Intervention: Retarded subjects
Number of subjects: 16
Study 7446596 — intervention group
Group type: COMPARATOR
Intervention: Nonretarded subjects
Number of subjects: 16
Study 6421778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (1800 kcal, 70 g protein) by naso-jejunal tube for 7-10 days
Number of subjects: 8
Study 6421778 — intervention group
Group type: COMPARATOR
Intervention: Unmodified hospital diet
Number of subjects: 8
Study 31930893 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with vibration training
Number of subjects: 60
Study 31930893 — intervention group
Group type: COMPARATOR
Intervention: Simple vibration training
Number of subjects: 60
Study 29437590 — intervention group
Group type: EXPERIMENTAL
Intervention: Total metabolic tumor volume (TMTV) measured on baseline PET
Number of subjects: 258
Study 29437590 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET (iPET2) findings
Number of subjects: 258
Study 29437590 — intervention group
Group type: COMPARATOR
Intervention: Combined modality treatment (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 258
Study 27722221 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate non-occlusally loaded implants
Number of subjects: 52
Study 27722221 — intervention group
Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 52
Study 27722221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 24773371 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable mesh fixed with absorbable tacks and/or fibrin glue
Number of subjects: 43
Study 24773371 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacks
Number of subjects: 43
Study 24773371 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacks plus fibrin glue
Number of subjects: 43
Study 23169801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive structured care (computer assisted clinical profiling and risk target setting, intensified follow-up, stepwise drug titration)
Number of subjects: 1562
Study 23169801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive structured care
Number of subjects: 1562
Study 23169801 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1562
Study 19709689 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/d, n = 19)
Number of subjects: 60
Study 19709689 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone (4 mg/d, n = 20)
Number of subjects: 60
Study 19709689 — intervention group
Group type: COMPARATOR
Intervention: placebo (medical nutrition therapy, n = 21)
Number of subjects: 60
Study 19192864 — intervention group
Group type: EXPERIMENTAL
Intervention: Deposit contract ($50.00)
Number of subjects: 8
Study 19192864 — intervention group
Group type: COMPARATOR
Intervention: No-deposit group
Number of subjects: 8
Study 15004572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3% (Ciloxan)
Number of subjects: 100
Study 15004572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ciprofloxacin and dexamethasone
Number of subjects: 100
Study 15004572 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone phosphate 0.1% (Maxidex)
Number of subjects: 100
Study 15004572 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear solution (Tears Naturale)
Number of subjects: 100
Study 11303266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg
Number of subjects: 105
Study 11303266 — intervention group
Group type: COMPARATOR
Intervention: Cefixime, 400 mg
Number of subjects: 105
Study 11303266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (MICs > or = 4.0 microg/mL)
Number of subjects: 105
Study 11303266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (MICs < 4.0 microg/mL)
Number of subjects: 105
Study 9164216 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy (750 mg/m2 daily fluorouracil on days 1 to 5 and 29 to 33, and 15 mg/m2 mitomycin on day 1)
Number of subjects: 110
Study 9164216 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 110
Study 9164216 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy
Number of subjects: 110
Study 7700062 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 4000000
Study 7700062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 4000000
Study 2438902 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermochemotherapy (hyperthermia combined with chemotherapy)
Number of subjects: 69
Study 2438902 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 69
Study 30094663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-based program delivered by lay volunteers (social interaction, nutritional and physical exercise interventions)
Number of subjects: 0
Study 27003163 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (soft elastomer roller)
Number of subjects: 24
Study 27003163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hard polystyrene roller)
Number of subjects: 24
Study 24169364 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS (atDCS)
Number of subjects: 0
Study 24169364 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (stDCS)
Number of subjects: 0
Study 22771293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Number of subjects: 198
Study 22771293 — intervention group
Group type: COMPARATOR
Intervention: Suture
Number of subjects: 198
Study 20397456 — intervention group
Group type: EXPERIMENTAL
Intervention: blood‐letting cupping plus herbal medicine
Number of subjects: 34
Study 17955168 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (traditional Chinese medicine)
Number of subjects: 409
Study 17955168 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (superficial needling at nonacupuncture points)
Number of subjects: 409
Study 17955168 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 409
Study 17955168 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 409
Study 16274386 — intervention group
Group type: EXPERIMENTAL
Intervention: High mortality risk group
Number of subjects: 2255
Study 16274386 — intervention group
Group type: COMPARATOR
Intervention: Low mortality risk group
Number of subjects: 2255
Study 12418393 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 0
Study 9845397 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 24
Study 9845397 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 24
Study 9845397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8010718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folinic acid (FA) plus fluorouracil (FU)
Number of subjects: 211
Study 8010718 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TS) added to FA-FU
Number of subjects: 211
Study 2658897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin therapy
Number of subjects: 46
Study 2658897 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-gentamicin therapy
Number of subjects: 46
Study 4921284 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-chlorthalidone
Number of subjects: 0
Study 4921284 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa-chlorthalidone
Number of subjects: 0
Study 31948512 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths for the Journey (SFJ) intervention
Number of subjects: 72
Study 31948512 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed group
Number of subjects: 72
Study 30154236 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated FiO2 adjustment
Number of subjects: 12
Study 30154236 — intervention group
Group type: COMPARATOR
Intervention: Manual FiO2 adjustment
Number of subjects: 12
Study 27899357 — intervention group
Group type: EXPERIMENTAL
Intervention: Inolimomab
Number of subjects: 100
Study 27899357 — intervention group
Group type: COMPARATOR
Intervention: ATG (usual care)
Number of subjects: 100
Study 26732807 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome Evaluation System (SES)
Number of subjects: 385
Study 26732807 — intervention group
Group type: COMPARATOR
Intervention: Blood Culture (BACTEC)
Number of subjects: 385
Study 25099872 — intervention group
Group type: EXPERIMENTAL
Intervention: web- and text messaging-based intervention providing online feedback and tailored text messages, up to two weekly messages for 3 months
Number of subjects: 934
Study 25099872 — intervention group
Group type: COMPARATOR
Intervention: assessment only (control group)
Number of subjects: 934
Study 22464991 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259
Study 22464991 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study 19545453 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured warm-up program at two training sessions per week throughout the 2009 competitive season (April to October)
Number of subjects: 516
Study 19545453 — intervention group
Group type: COMPARATOR
Intervention: Training and playing as usual (Control group)
Number of subjects: 516
Study 17309596 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (N=23)
Number of subjects: 92
Study 17309596 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 500 mg azithromycin per day for 3 days (N=25)
Number of subjects: 92
Study 17309596 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 250 mg metronidazole tid for 14 days (N=24)
Number of subjects: 92
Study 17309596 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 20 mg doxycycline bid for 3 months (N=20)
Number of subjects: 92
Study 15125464 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (omeprazole, amoxycillin and metronidazole) for H. pylori-positive patients (Hp+/erad)
Number of subjects: 1552
Study 15125464 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for H. pylori-positive patients (Hp+/ome)
Number of subjects: 1552
Study 15125464 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/ome)
Number of subjects: 1552
Study 15125464 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/erad)
Number of subjects: 1552
Study 15125464 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative patients (Hp-/ome)
Number of subjects: 1552
Study 11591944 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified carbon dioxide (CO2)
Number of subjects: 40
Study 11591944 — intervention group
Group type: COMPARATOR
Intervention: Standard dry carbon dioxide (CO2)
Number of subjects: 40
Study 10457551 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 800 mg injection of Pefloxacin (PF)
Number of subjects: 616
Study 10457551 — intervention group
Group type: COMPARATOR
Intervention: 2 days of cefazolin (1 gr.Q.6 H) followed by 3 days of oxacillin (1 gr.Q.8 H) (CZ-OX)
Number of subjects: 616
Study 10457551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (PF)
Number of subjects: 616
Study 10457551 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin-oxacillin (CZ-OX)
Number of subjects: 616
Study 10457551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 616
Study 8574175 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (L-leucine 12 g, L-isoleucine 6 g, L-valine 6 g daily)
Number of subjects: 24
Study 8574175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8574175 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 8574175 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 8574175 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids
Number of subjects: 24
Study 2222100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus rifampin
Number of subjects: 21
Study 2222100 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole and trimethoprim plus rifampin
Number of subjects: 21
Study 895002 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-acetyldigoxin
Number of subjects: 0
Study 895002 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-acetyldigoxin
Number of subjects: 0
Study 895002 — intervention group
Group type: EXPERIMENTAL
Intervention: new formulation isolating beta-acetyldigoxin from potassium-magnesium-aspartate
Number of subjects: 0
Study 31882586 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor surgery (S)
Number of subjects: 1415
Study 31882586 — intervention group
Group type: COMPARATOR
Intervention: No surgery (non-S)
Number of subjects: 1415
Study 28236780 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centred, feedback-informed intervention
Number of subjects: 26
Study 25788569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose human menopausal gonadotrophin (hMG) 37.5-75 IU per day
Number of subjects: 330
Study 25788569 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg/day from Day 3-7
Number of subjects: 330
Study 25788569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose human menopausal gonadotrophin (hMG)
Number of subjects: 330
Study 25788569 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 330
Study 24373363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (6 hours nightly)
Number of subjects: 87
Study 24373363 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise cessation
Number of subjects: 87
Study 24373363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sleep restriction and exercise cessation
Number of subjects: 87
Study 24373363 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 87
Study 21389925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized Regenerated Cellulose (ORC) applied to surgical wounds
Number of subjects: 98
Study 21389925 — intervention group
Group type: COMPARATOR
Intervention: Gauze soaked in iodine
Number of subjects: 98
Study 19153941 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 to 8 mg daily)
Number of subjects: 30
Study 19153941 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 16953261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 60 mg t.i.d.
Number of subjects: 371
Study 16953261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 120 mg t.i.d.
Number of subjects: 371
Study 16953261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 240 mg t.i.d.
Number of subjects: 371
Study 16953261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 16953261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat (all doses)
Number of subjects: 371
Study 15372383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bier block with methylprednisolone (40 mg) and lidocaine (10 mL of 2% solution)
Number of subjects: 22
Study 15372383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL of saline)
Number of subjects: 22
Study 15372383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bier block with methylprednisolone and lidocaine
Number of subjects: 22
Study 15372383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11465642 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg patches)
Number of subjects: 0
Study 9604636 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (15 treatments over 3 months)
Number of subjects: 22
Study 9604636 — intervention group
Group type: COMPARATOR
Intervention: Individualised physiotherapy
Number of subjects: 22
Study 1620298 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-175 (Group A: 20 mg every 12 hours for 4 days; Group B: 20 mg every 6 hours for 4 days; Group C: 40 mg every 6 hours for 4 days)
Number of subjects: 23
Study 1620298 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-175 (higher doses: Groups B and C)
Number of subjects: 23
Study 1620298 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-175 (all groups)
Number of subjects: 23
Study 1620298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FUT-175)
Number of subjects: 23
Study 6366808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg serrapeptase 3 times on the day before operation, once on the night of the operation and 3 times daily for 5 days after operation
Number of subjects: 174
Study 6366808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 31437295 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive text messaging with key details from the class
Number of subjects: 0
Study 31437295 — intervention group
Group type: COMPARATOR
Intervention: No text messages (Control group)
Number of subjects: 0
Study 30064993 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care (PC)
Number of subjects: 302
Study 30064993 — intervention group
Group type: COMPARATOR
Intervention: Sleep Unit (SU)
Number of subjects: 302
Study 30064993 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI)
Number of subjects: 302
Study 27287832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 317
Study 27287832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 317
Study 27287832 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 317
Study 27287832 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab plus methotrexate vs Methotrexate
Number of subjects: 317